TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05353530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Description: Single dose of 8R-70CAR T cells administered IV
Study: NCT06669572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be taken once daily, with or without food, at the same time each day.
Study: NCT06295159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Opdualag (Nivolumab and Relatlimab-rmbw) is a combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3). Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response.
Study: NCT05975905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose A KER-012
Description: Dose A KER-012 (Q4W);
Study: NCT05290519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plant and animal protein
Description: plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plant and animal protein
Description: plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
Study: NCT05975905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose B KER-012
Description: Dose B KER-012 (Q4W);

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Dose B KER-012
Description: Dose B KER-012 (Q4W);

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose C KER-012
Description: Dose C KER-012 (Q4W);
Study: NCT04799119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do As I Do (DAID) dog training
Description: Children and their family dog will participate in this dog training program.
Study: NCT06091787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT05871892

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18F-FDGal PET/CT or PET/MRI
Description: All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
Study: NCT05072886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT193
Description: Topical applied to affected areas daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AT193
Description: Topical applied to affected areas daily
Study: NCT06745128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 32-week period. Following the instructions of the FDA-approved prescribing label, participants or a licensed study clinician will administer the tirzepatide injection subcutaneously in either the abdomen, thigh, or upper arm once weekly for 32 weeks total. Following the instructions of the FDA-approved prescribing label, the dosing schedule will include a 4-week titration at a starting dosage of 2.5mg/week. After four weeks, dosage will be increased in 2.5mg increments. The recommended maintenance dosages per prescribing label are 5mg/week, 10mg/week, or 15mg/week injected subcutaneously. Maximum dosage (up to 15mg/week) will be optimized for each individual. We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue, MOUNJARO® may be dispensed as an alternative.
Study: NCT06744673

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06745076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05975905

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
Description: Treatment Period (24 weeks): Placebo SC (Q4W) Extension Period (72 weeks after Placebo treatment): KER-012 (Dose B) SC (Q4W)
Study: NCT06607913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participants will exercise 2 days a week for 16 weeks. The exercises will include 4 movements: squats, shoulder press, seated row, and bicep curl focusing on internal load and contraction velocity.
Study: NCT06745076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT05393908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block Group
Description: Participants will receive a surgeon administered TAP block.
Study: NCT06668571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
Study: NCT06614842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Factors Group Psychotherapy
Description: This intervention will not contain active ingredients from established specific forms of psychotherapy (e.g., cognitive-behavioral therapy, dialectical behavioral therapy)
Study: NCT06661915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo buccal swab and blood sample collection
Study: NCT04927988

Intervention type: OTHER
Group type: OTHER
Intervention: Ringer's Lactated
Description: Using of Ringer's Lactated In Autologous Blood Cell Transfusion
Study: NCT06331572

Intervention type: DIAGNOSTIC_TEST
Intervention: 17-HAMD
Description: Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: 17-HAMD
Description: Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: 17-HAMD
Description: Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
Study: NCT06209996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: L4 weight management intervention
Description: he key goals of the intervention are to: (i) teach knowledge of weight loss benefits and health risks of obesity, (ii) offer skill-based dietary and physical activity advice, (iii) develop an achievable weight loss goal and plan, (iv) enhance weight management self-efficacy, (v) provide access to exercise equipment and resources, and (vi) teach strategies for managing cravings. The L4 intervention is a therapist- delivered intervention involving a registered dietitian and a cancer exercise specialist. Participants allocated to the intervention arm will be provided with a schedule to attend the L4 intervention within four weeks post-baseline via phone. They will receive five intervention sessions (120 min each) on a weekly basis, and will be given home-based practices and reading to practice the skills learnt in each session. The intervention sessions will be delivered in a group format with a maximum of 5 individuals per group, which is likely to enhance accountability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging, and be encouraged to follow the advice covered in the videos. The materials will be developed based on the existing dietary and physical activity guidelines for cancer survivors. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
Study: NCT06465654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated variable dose oxygen treatment
Description: The participant will receive closed loop oxygen titration during a walking test based on oxygen saturation measurements every second measured by a pulse oximeter connected to the O2matic. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed dose oxygen treatment
Description: The participant will receive a fixed oxygen dose during a walking test. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
Study: NCT05575245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting Stent
Description: Drug-eluting Stent angioplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser Ablation Combined Drug-coated Balloon
Description: Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
Study: NCT06745076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study: NCT06661915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo buccal swab and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study: NCT05782244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate low dose
Description: Sildenafil citrate 20 mg, oral, TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil medium dose
Description: Sildenafil 40 mg, oral, TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil high dose
Description: Sildenafil 80 mg, oral, TID
Study: NCT04669093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo cream- promotion suggestion
Description: Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo cream- prevention suggestion
Description: Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control cream
Description: In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
Study: NCT06432452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin Receptor Antagonist
Description: Oral capsules twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Oral capsules twice daily
Study: NCT04702750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (odors)
Description: I will unobtrusively and repeatedly present learning-related odors during sleep using an olfactometer. This method was shown to improve memory in various tasks. The odors will be presented in blocks with short breaks in-between. Odors will be pleasant as to not wake the participant up. The odors will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The odors presented will be non-congruently associated with instructions in a previous learning task. This manipulation is within-subject - all participants will be exposed to all the odors during sleep, but odors will be associated with different instructions for each participant (counterbalanced).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (sounds)
Description: I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will be exposed to sounds, but different specific sounds will be presented for each individual participant.
Study: NCT05746884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duodenal mucosectomy
Description: Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: duodenal mucosectomy
Description: Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ampullectomy
Description: Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ampullectomy
Description: Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
Study: NCT05337696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebral Implant PEEK Procedure
Description: Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertebral Implant PEEK (VIP) implant
Description: The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
Study: NCT05576207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced energy and protein supplement for pregnant women
Description: A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced energy and protein supplement for pregnant women
Description: A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced energy and protein supplement for pregnant women
Description: A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Micronutrient Supplement for pregnant women
Description: Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group.
Study: NCT06250257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine mesylate plus standard GDMT
Description: The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate plus standard GDMT
Description: The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
Study: NCT06222424

Intervention type: OTHER
Group type: OTHER
Intervention: outpatient prescription issues
Description: Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
Study: NCT05815784

Intervention type: DRUG
Group type: OTHER
Intervention: Atropine
Description: 0.05% atropine. One drop per eye per day for 2 years.
Study: NCT06745076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Complete questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Complete questionnaire
Study: NCT06743659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alert-based computerized decision support
Description: A program will be designed to run within the Electronic Health Record (EHR) that will identify outpatients with definite, probable, or possible diagnosis of FH. The BPA will calculate the Dutch Lipid Clinic Network score using the following EHR data:~1. Maximum LDL-C level in the laboratory results~2. Abnormal genetic testing for FH in the laboratory results~3. Medical history or problem list entry for tendinous xanthomata or arcus cornealis~4. Medical history, visit diagnosis, or problem list entry of premature CAD, cerebrovascular disease, or PAD~5. Family history of premature CAD, cerebrovascular disease, or PAD~In the Alert phase, an on-screen alert will notify the ambulatory care clinician of record that the patient has a definite, probable, or possible diagnosis of FH. ambulatory care clinician will have the opportunity to proceed to an order template through which a referral for specialty care focused on evaluation and management of FH can be made.